Researcher

Rezvan Abduljabbar

National Merit Scholarship Corporation

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

SEP 4, 2026 · JOURNAL ARTICLE

Hypersensitivity Reactions to Anticancer Drugs: A Prospective Study at Azadi Hematology Oncology Center, Duhok

Advanced Medical Journal

Single-centre prospective observational study over 9 weeks with small absolute number of events (n=7) reporting incidence rate; descriptive rather than comparative, and lacks control or mechanistic depth to support generalization.

PreliminaryLung Cancer Treatments and Mutations Cancer, Stress, Anesthesia, and Immune Response Rezvan Abduljabbar

Reported

Incidence rate0.32%

Sample size2160

Hypersensitivity events7

SEP 4, 2026 · JOURNAL ARTICLE

The Outcome of Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Single-Institute Experience

Advanced Medical Journal

Single-centre retrospective study of 141 patients with observational outcomes; no randomised comparator, no prospective design, and no hard clinical endpoints with effect sizes reported.

PreliminaryRamadhan Tayeb Othman Othman Iman Abdulhakim Dawod Dawod Cancer Treatment and Pharmacology

Reported

Sample size141

P-value (invasive ductal vs lobul…0.008

P-value (breast-conserving surger…<0.0001